Pluristem contracts CRO for Phase I trial of PLX-R18
Pluristem has advanced its Phase I trial of PLX-R18 cells to treat insufficient haematopoietic recovery following haematopoietic cell transplantation (HCT) by contracting with a leading global clinical research organisation (CRO).
Click on this link for more information.
